Laurus Labs Limited
Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs and oral solid formulations for advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, anti-asthma, ophthalmology, oncology, gastroenterology, and hepatitis C therapeutic areas. It also provides biotechnology services used in the nutraceutical, dietary supplements, alternate food proteins, and cosmeceutical products. In addition, the company develops novel enzymatic solutions for industrial biotechnology, and animal origin free recombinant proteins and enzymes for biopharma; and offers business support services for pharmaceuticals field. Laurus Labs Limited was incorporated in 2005 and is based in Hyderabad, India.
Valuation
Profitability
Returns
Solvency
AI Summary
Indian StockStrengths1
- Large-cap with βΉ57.2K Cr market capitalisation
Concerns1
- Low return on equity of 5.3%
Rule-based from financial data. Not advice.
Monthly Returns
Year-to-Date ROI
Historical Volatility
Historical Performance
Revenue, profitability, and cash flow trends (βΉ Crores)
Revenue (10Y)
Operating Income (10Y)
Net Profit (10Y)
Operating Margin % (10Y)
Dividend Payout % (10Y)
Free Cash Flow (10Y)
Growth Summary
Latest fiscal year: Mar 2025
Historical Growth
Year-by-year revenue, profitability, and cash flow (βΉ Crores, last 10 years)
| Year | Revenue | Op. Income | Net Profit | CFO | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|---|
| Mar 2025 | βΉ5.22 K Cr | β | βΉ380.00 Cr | β | β | 8.3% | 8.4% | 69.6% |
| Mar 2024 | βΉ4.81 K Cr | β | βΉ224.00 Cr | β | β | 5.3% | -16.6% | -70.5% |
| Mar 2023 | βΉ5.77 K Cr | β | βΉ760.00 Cr | β | β | 18.7% | 22.6% | 1.3% |
| Mar 2022 | βΉ4.71 K Cr | β | βΉ750.00 Cr | β | β | 22.1% | -1.3% | -21.5% |
| Mar 2021 | βΉ4.77 K Cr | β | βΉ956.00 Cr | β | β | 35.3% | 70.5% | 258.1% |
| Mar 2020 | βΉ2.80 K Cr | β | βΉ267.00 Cr | β | β | 14.7% | 25.1% | 181.1% |
| Mar 2019 | βΉ2.24 K Cr | β | βΉ95.00 Cr | β | β | 6.0% | 10.3% | -45.1% |
| Mar 2018 | βΉ2.03 K Cr | β | βΉ173.00 Cr | β | β | 11.4% | 7.1% | -13.5% |
| Mar 2017 | βΉ1.89 K Cr | β | βΉ200.00 Cr | β | β | 14.7% | 6.6% | 37.9% |
| Mar 2016 | βΉ1.77 K Cr | β | βΉ145.00 Cr | β | β | 18.0% | 33.9% | 95.9% |
Financial Statements
Income statement, balance sheet, and cash flow (βΉ Crores, as reported)
Consolidated Figures in USD Millions.
| Unnamed: 0 | TTM |
|---|---|
| Revenue / Net Sales | 5,915 |
| Total Expenses | 4,596 |
| EBIT / Operating Profit | 1,318 |
| OPM % | 22% |
| Other Income | 129 |
| Finance Costs | 174 |
| Depreciation & Amortisation | 366 |
| Profit Before Tax | 907 |
| Tax % | - |
| Net Profit / PAT | 683 |
| EPS (βΉ) | 12.66 |
| Dividend Payout % | - |
Peer Comparison
Healthcare sector peers, ranked by market cap
| Company | Market Cap | Revenue | P/E | P/B | EV/EBITDA | Rev G 1Y |
|---|---|---|---|---|---|---|
| Laurus Labs Limitedthis co. | βΉ57.18 K Cr | βΉ5.22 K Cr | 83.80 | 11.61 | 73.34 | 8.4% |
| Sun Pharmaceutical Industries Ltd. | βΉ4.15 L Cr | βΉ23.00 K Cr | 88.70 | 17.43 | 72.30 | 13.5% |
| Divi's Laboratories Ltd. | βΉ1.71 L Cr | βΉ9.20 K Cr | 67.90 | 11.13 | 67.21 | 20.0% |
| Torrent Pharmaceuticals Ltd. | βΉ1.33 L Cr | βΉ9.68 K Cr | 62.50 | 15.76 | 45.64 | 13.5% |
| Cipla Ltd. | βΉ1.17 L Cr | βΉ19.05 K Cr | 22.50 | 3.51 | 19.33 | 14.9% |
| Apollo Hospitals Enterprises Ltd. | βΉ1.05 L Cr | βΉ8.20 K Cr | 75.00 | 11.28 | 54.44 | 12.8% |
| Max Healthcare Institute Limited | βΉ1.00 L Cr | βΉ2.66 K Cr | 144.00 | 11.76 | 96.84 | 13.8% |
| Industry Average | β | βΉ3.29 K Cr | 98.63 | 8.11 | 65.50 | 20.2% |